Cost-effectiveness analysis of TAVR.

Area of Science:

• Cardiovascular Medicine
• Health Economics
• Medical Technology Assessment

Background:

• Transcatheter aortic valve replacement (TAVR) is increasingly used for symptomatic severe aortic stenosis in high-risk patients.
• Two main TAVR systems, Edwards SAPIEN and Medtronic CoreValve, are established globally and undergoing trials in the US.
• TAVR adoption is significant in Europe, representing 23% of tissue valve replacements in older adults.

Purpose of the Study:

• To examine the current understanding of the cost-effectiveness of Transcatheter Aortic Valve Replacement (TAVR).
• To address the economic implications of TAVR in the context of rising healthcare costs.
• To review data from trials like PARTNER and CoreValve that incorporate cost-effectiveness analysis.

Main Methods:

• Analysis of existing medical literature and clinical trial data focusing on TAVR.
• Review of cost-effectiveness studies for TAVR procedures.
• Examination of data from pivotal trials (e.g., PARTNER, CoreValve) that include economic endpoints.

Main Results:

• TAVR is a viable option for patients deemed too high-risk for conventional surgery.
• The cost-effectiveness of TAVR has been a key consideration in major clinical trials.
• Growing use of TAVR necessitates a thorough understanding of its economic value.

Conclusions:

• The cost-effectiveness of TAVR is a critical factor in its widespread adoption and future healthcare planning.
• Further research and ongoing trials are essential to fully elucidate the long-term economic benefits of TAVR.
• TAVR teams, advanced imaging, and expensive devices contribute to the overall cost profile that must be weighed against clinical outcomes.